Home  >  News
Marketing
+ Font Resize -

EnvoyHealth signs co-marketing partnership with PharMedQuest for ARC medical benefit drug management platform

Flint, Michigan
Wednesday, August 16, 2017, 16:00 Hrs  [IST]

EnvoyHealth, a Diplomat company, signs co-marketing agreement with PharMedQuest for combined oncology drug management solutions.

EnvoyHealth, a Diplomat company, has agreed to a co-marketing partnership with PharMedQuest for its ARC medical benefit drug management platform.

PharMedQuest’s ARC program platform will provide EnvoyHealth an advanced solution for managing high-cost oncology drug medications.

ARC enables payors and providers to optimize clinical and financial outcomes for treatment of cancer conditions. Through state-of-the art technology and clinical expertise, it offers real-time data that optimally manages oncology therapy under the medical benefit. In partnership, EnvoyHealth and PharMedQuest provide comprehensive oncology management solutions under the pharmacy benefit and medical benefit.

“We are thrilled to expand our service expertise and portfolio by partnering with PharMedQuest,” said Atheer Kaddis, EnvoyHealth’s executive vice president of sales and strategic alignment. “Our full-service model allows us to customize solutions for our partners to demonstrate value, cost-effectiveness, and outcomes to manage the oncology marketplace dynamics. EnvoyHealth’s enhanced service offerings will help our partners meet their objectives in a way that delivers real value.”

“We are excited to partner with EnvoyHealth on this new strategic initiative providing a uniquely innovative approach to managing high-cost oncology drugs,” said Kirby Eng, vice president of business development at PharMedQuest. “Integrating ARC™ with EnvoyHealth’s depth and breadth of complementary specialty drug dispensing, clinical, and patient care management capabilities will enable payors and plan sponsors to collaborate with providers to ensure clinical and cost-effective utilization of high-cost oncology medications for patients afflicted with cancer.”

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
IPJPI_150x60en_2017
acssymposium
CPhI-WWW-150x60-stat-v1
PHARMACONNECT_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |